Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:11:57.826Z.
Consensus retrieved: 2026-10-06T11:14:33.957Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:11:57.826Z.
Quote observation: 2026-10-06T15:08:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2d15fccd73dd71321fa30efb235d10704747171fee005d1a5dd6499fafc6c703
Forward PE Ratio (N/A) = Dated Quote Price ($0.47) / Consensus Forward EPS ($-0.25)
FORWARD PE RATIO
N/A
Estrella Immunopharma, Inc.
Market Cap
$19.96M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | $19.96M | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.23M | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.92M | N/A |
| Modular Medical, Inc. (MODD)vs › | $21.13M | N/A |
| NextCure, Inc. (NXTC)vs › | $18.60M | N/A |
| Cosmos Health Inc. (COSM)vs › | $18.38M | N/A |
| LeonaBio, Inc. (LONA)vs › | $21.87M | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.43M | N/A |
| Lipocine Inc. (LPCN)vs › | $17.07M | N/A |
| PAVmed Inc. (PAVM)vs › | $17.04M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.47, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.25 | $-0.25 – $-0.25 | 1 | n/m |
| 2027-12-31 | $-0.32 | $-0.32 – $-0.32 | 1 | n/m |
| 2028-12-31 | $-0.31 | $-0.31 – $-0.31 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
